You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Electronic Image Trial Management System

    SBC: VIRTUALSCOPICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Delays in FDA drug approval are measured in lost lives (estimated to be hundreds of thousands over the last few decades) and increased costs to U.S. citizens for drugs that are eventually approved. One factor contributing to the delay in drug approvals is the widespread use of time-consuming and error-prone manual methods to deliver medical images (i.e. CT, MR, ...

    STTR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  2. Ridge Waveguide Structures in Magnesium-Doped Lithium Niobate

    SBC: ADVR, INC.            Topic: T401

    In this NASA Phase I STTR effort, the feasibility of fabricating isolated ridge waveguides in 5% magnesium-doped lithium niobate (5% MgO:LN) will be established. Ridge waveguides in MgO:LN will significantly improve the power handling and conversion efficiency, increase photonic component integration, and be well suited to space based applications. The key innovation in this effort is to combine ...

    STTR Phase I 2009 National Aeronautics and Space Administration
  3. Cardiac Regenerative Therapy with Cyclin A2

    SBC: VentriNova, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): The morbidity and mortality due to cardiovascular disease is attributed to the lack of significant replicative potential of adult mammalian cardiomyocytes. Thus myocyte loss in response to ischemic injury typically results in scar formation and a decline of cardiac function that is usually irreversible. The cessation of myocyte proliferation is associated with ...

    STTR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  4. Clinical Testing of an Insulin Analog

    SBC: THERMALIN DIABETES, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The central goal of insulin replacement therapy in the treatment of Type 1 diabetes mellitus (T1DM) is tight control of blood glucose concentration. This Phase I STTR application, submitted by Thermalin Diabetes, Inc., in conjunction with Case Western Reserve University, seeks support for the pre-clinical testing and commercial development of an ultra-stable a ...

    STTR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  5. Radioprotection by use of Topical Lithium Formulations

    SBC: CUMBERLAND PHARMACEUTICALS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Roughly 500,000 cancer patients are treated with radiotherapy each year. Acute and late sequelae of radiotherapy have a negative impact upon the quality of life of cancer survivors. These sequelae include proctitis, cystitis, esophageal stricture, cutaneous fibrosis plus others. We propose a novel means of preventing the acute and late radiation injury to norma ...

    STTR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  6. Mannan, A Potential Therapeutic for Asthma

    SBC: CUMBERLAND PHARMACEUTICALS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The long-term goal of this application is to develop mannan derived from Baker's yeast as asthma therapy. The limitations of currently available immunomodulators are their toxicity at higher doses and the lack of beneficial effect on airway smooth muscle (ASM) remodeling and therefore, new adjunctive therapeutics are needed. Initial findings in the P.I.'s labor ...

    STTR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  7. Functional Tissue Engineering for Cartilage Repair

    SBC: Cytex Therapeutics, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Degenerative joint diseases such as osteoarthritis remain the source of significant pain and disability, affecting 20 million adults with an economic burden of over 40 billion per year to the United States. While joint replacement is a well-established procedure, its finite life span makes this treatment unacceptable for younger or more active individuals, of ...

    STTR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  8. Rapid and Efficient PCR Cleanup Filters

    SBC: DIFFINITY GENOMICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Analysis of DNA is important in many applications including forensics, diagnostic genetic testing and biomedical research. Genomic DNA analysis uses chemical amplification methods such as polymerase chain reaction (PCR) amplification of a target sequence to increase the amount of the genetic fragment under study. This is essential for sequencing which promises ...

    STTR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  9. Fast Spectral Imaging Device For Tumor Margin Mapping

    SBC: Zenalux Biomedical, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): The American Cancer Society estimates that a total of 240,430 new breast cancers were diagnosed in 2007 (178,400 new cases of invasive breast cancer, and 62,030 new cases of in situ breast cancer). Approximately 180,000 of these patients undergo breast conserving surgery (BCS), also called lumpectomy. Multiple recent studies show that a staggering 20-70% of the ...

    STTR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  10. Development of ADAM10 Prodomain as a Therapeutic Agent

    SBC: BIOZYME, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Recent cancer therapies have focused on using biologics to target specific signal transduction pathways implicated in the tumor development or progression. For example, recombinant fusion proteins consisting of the extracellular domain of the immunoregluatory proteins and the constant (Fc) domain of immunoglobulin (IgG) represent a growing class of protein ther ...

    STTR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government